Clinical Trial Update: A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004) [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation and safety trial of I5NP to prevent acute kidney injury in high-risk cardiovascular surgery patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• I5NP (I5NP)

Snippet

Sponsor: Quark Pharmaceuticals | Conditions: Acute Renal Failure, Acute Kidney Injury | Phase 1 | Status: TERMINATED